Regadenoson for the treatment of COVID-19: A five case clinical series and mouse studies is a research paper published in PLoS ONE (2023). On theSindex it has a DataRank of 0. It has been cited 12 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
NHLBI Division of Intramural Research
Grant: R01HL128492-05S1
Astellas Pharma US
Grant: ISR005923
Manning Fund
Grant: MC10
Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases
Grant: R01AI145108
Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases
Grant: P01 AI116501
NHLBI NIH HHS
Grant: R01 HL128492
NHLBI NIH HHS
Grant: R01 HL095704
National Institutes of Health
Grant: 2R01AI145108-07
The Role of Donor-Derived Eosinophils on Lung Allograft Ischemia Reperfusion Injury
National Institutes of Health
Grant: 5P01AI116501-04
Pathways Regulating Lung Transplant Tolerance
National Institutes of Health
Grant: 1R01HL128492-01A1
Prevention of Lung Transplant Injury with Adenosine 2A Receptor Agonist
FWCI
2.02
Citation Percentile
0.9%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals